Symphonix Suit Charges Soundtec With Misappropriating Trade Secrets
This article was originally published in The Gray Sheet
Executive Summary
Soundtec should be restrained from selling its Direct System implantable middle-ear hearing device for two years and give all related profits to Symphonix Devices, according to a complaint filed in the U.S. District Court for Northern California Nov. 27
You may also be interested in...
Symphonix' Vibrant Soundbridge
Incorporation of advanced eight-channel digital signal processing component into the semi-implantable middle-ear hearing device gains FDA approval via PMA supplement Jan. 3. Increasing programming flexibility, the next-generation device follows the August 2000 approval of the first generation product (1"The Gray Sheet" Sept. 4, 2000, p. 7). A totally implantable device also is under development
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.